Singh Prabhsimranjot, Toom Sudhamshi, Avula Akshay, Kumar Vivek, Rahma Osama E
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
J Hepatocell Carcinoma. 2020 Feb 10;7:11-17. doi: 10.2147/JHC.S187121. eCollection 2020.
Locoregional therapies (LRTs) including radiofrequency ablation, surgical resection, and TACE, play a pivotal role in the treatment of early stage/locally advanced hepatocellular carcinoma (HCC). Besides their direct effect on tumor cells, LRTs also play an essential role in the immunomodulation of the tumor microenvironment which is of interest in the current era of cancer immunotherapy. In this review, we describe the HCC immune microenvironment and how it is affected by LRTs as described in multiple pre-clinical and clinical studies and provide the rationale for combining LRTs with immunotherapy.
包括射频消融、手术切除和经动脉化疗栓塞术（TACE）在内的局部区域治疗（LRTs）在早期/局部晚期肝细胞癌（HCC）的治疗中起着关键作用。除了对肿瘤细胞的直接作用外，LRTs在肿瘤微环境的免疫调节中也起着重要作用，这在当前的癌症免疫治疗时代备受关注。在这篇综述中，我们描述了HCC免疫微环境以及多项临床前和临床研究中所描述的LRTs对其的影响，并提供了将LRTs与免疫治疗相结合的理论依据。
